Dianthus Therapeutics, Inc

Company snapshot

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory

• 6 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 US patent(s) indexed to this assignee profile.
• 6 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Dianthus Therapeutics, Inc. Not investment advice.

• Peer + 0 momentum

  Argenx

  TA overlap score 36.4

• Peer + 0 momentum

  Aurinia Pharmaceuticals

  TA overlap score 22.8

Recent activity

Latest pipeline, patent, and corporate events for Dianthus Therapeutics, Inc.

1. Jun 8, 2026 Clinical update

   DNTH103-MG-201 — Phase 2

2. Jun 5, 2026 Clinical update

   DNTH103, Matching placebo to DNTH103 — Phase 2

3. Jun 5, 2026 Clinical update

   Placebo matching DNTH103, DNTH103 — Phase 3

4. May 23, 2026 Clinical update

   Claseprubart — Phase 3

5. May 23, 2026 Clinical update

   Claseprubart — Phase 2

View all clinical trial activity →

• What is Dianthus Therapeutics, Inc?

  Dianthus Therapeutics, Inc is a pharma organization headquartered in New York City, USA. It trades on NYSE under ticker DNTH. Primary therapeutic focus areas include Chronic Inflammatory Demyelinating Polyneuropathy, Multifocal Motor Neuropathy, Generalized Myasthenia Gravis, Mya

• Is Dianthus Therapeutics, Inc publicly traded?

  Yes. Dianthus Therapeutics, Inc is listed with ticker DNTH on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Dianthus Therapeutics, Inc develop or market?

  We link 12 drug profile(s) where Dianthus Therapeutics, Inc is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/dianthus-therapeutics-inc-de#company-drugs.

• What are the latest developments for Dianthus Therapeutics, Inc?

  In the last 12 months our linked public records show 6 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Dianthus Therapeutics, Inc focus on?

  Dianthus Therapeutics, Inc focuses on Chronic Inflammatory Demyelinating Polyneuropathy, Multifocal Motor Neuropathy, Generalized Myasthenia Gravis based on our analysis of their pipeline programs and drug development activities.